Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Amgen Inc. (NASDAQ:AMGN) by 62.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 276,553 shares of the medical research company’s stock after purchasing an additional 106,374 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.05% of Amgen worth $79,653,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of AMGN. Vanguard Group Inc. raised its stake in Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares during the period. Morgan Stanley raised its stake in Amgen by 12.9% during the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after acquiring an additional 1,523,665 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Amgen by 1.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after acquiring an additional 94,565 shares during the period. Moneta Group Investment Advisors LLC raised its stake in Amgen by 83,875.6% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares during the period. Finally, Northern Trust Corp raised its stake in Amgen by 3.8% during the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after acquiring an additional 255,463 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.0 %

Amgen stock traded up $0.13 during midday trading on Tuesday, reaching $265.64. The stock had a trading volume of 2,011,146 shares, compared to its average volume of 2,871,692. The firm’s fifty day simple moving average is $279.63 and its two-hundred day simple moving average is $281.52. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $142.36 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same quarter last year, the business posted $4.09 EPS. The company’s revenue was up 19.8% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.39%. Amgen’s payout ratio is 72.06%.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. Morgan Stanley dropped their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and raised their price target for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and raised their price target for the company from $264.00 to $320.00 in a research note on Thursday, December 21st. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Finally, StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Ten equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.